title: New drug developments in the Netherlands. "Tetracyclic" psychotropic drugs.
abstract: Based on qualitative and quantitative EEG findings, the psychotropic properties of GB-94, GC-46, and GC-94 were predicted. According to the EEG model, GB-94 was predicted to be similar to amitriptyline and GC-46 t( imipramine. GC-94 was found to be much less effective on the CNS than GB-94 and GC-46 and was predicted to have "stimulatory" clinical effects similar to desipramine. The clinical trials demonstrated that GB-94 is indeed an antidepressive psychotropic compound similar to amitriptyline. GB-94 in lower dosages was also found to be effective in anxiety syndromes. In some schizophrenics GB-94 showed some therapeutic effects, while in others it obviously exacerbrated the psychotic symptomatology. GC-94 was not found to be significantly effective in a heterogenous psychiatric population. Only slight improvement in some schizophrenic patients was observed However, a noticeable worsening in the symptomatology of manic and hypomanic patients was seen. The study demonstarted that GC-94 indeed has a central stimulatory effect, but no minor or major tranquilizer properties or sedative antidepressive qualities were observed. GC-46 was tried in only three subjects. Based on this pilot trial, no conclusion can be made about the psychotropic properties of this compound. Our quantitative pharmaco-EEG and clinical trials clearly demonstrated the significant value of quantitative EEG in early screening of psychoactive drugs in order to predict their clinical values and effective dosage ranges.
authors: Department of Psychiatry, New York Medical College, USA.
authors: T M
authors: TM
authors: Itil
authors: N
authors: N
authors: Polvan
authors: K
authors: K
authors: Dincmen
authors: S
authors: S
authors: Egilmez
authors: K
authors: K
authors: Sungerbey
mesh_terms: D000275:Adjustment Disorders / Q000188:drug therapy / Q000503:physiopathology; D001008:Anxiety Disorders / Q000188:drug therapy; D001714:Bipolar Disorder / Q000188:drug therapy / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003989:Dibenzoxazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D015507:Drugs, Investigational / Q000737:chemistry; D004569:Electroencephalography; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000503:physiopathology; D008803:Mianserin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009426:Netherlands; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D003989:Dibenzoxazepines; D015507:Drugs, Investigational; D011619:Psychotropic Drugs; D012702:Serotonin Antagonists; D008803:Mianserin; C002340:GC-46